New drug aims to cut opioid use after knee surgery
NCT ID NCT07548385
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether Suzetrigine, a new pain medication, can improve pain control and reduce opioid use after total knee replacement. About 235 adults scheduled for knee surgery will be randomly assigned to receive either Suzetrigine or a placebo, in addition to standard pain care. The study measures how much opioid painkiller participants need and their pain scores on a 0-10 scale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Suzetrigine (a new pain medication that blocks pain signals from nerves)
What this could lead to
If it works, this could provide a new option for managing pain after knee replacement, potentially reducing the need for opioids.
What could go wrong
This is a Phase 3 trial, but results may not show a significant benefit over existing treatments. The drug is still investigational and may have unknown side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST OPERATIVE PAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mount Sinai West
RECRUITINGNew York, New York, 10019, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••